secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0000914475-25-000139
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine CMO Eiry Roberts to step down; Sanjay Keswani named successor June 2, 2025
--------------------------------------------------------------------------------

- Dr. Eiry Roberts transitions from CMO to Strategic Advisor to the CEO, effective June 2, 2025 through Dec 31, 2025.
- Dr. Sanjay Keswani will succeed Dr. Roberts as Chief Medical Officer, effective June 2, 2025.
- Dr. Roberts receives annual base salary of $731,400 and target bonus of 60% of base pay in new advisory role.
- Outstanding equity awards continue vesting; severance terms substantially unchanged from prior agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000139/0000914475-25-000139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000139/nbix-20250530.htm
  HTML page:      https://secwatch.observer/filing/0000914475-25-000139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer